Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy

AAPS Journal

Volumn 8, Issue 3, 2006, Pages 552-563

  Agoram, Balaji ^a   Heatherington, Anne C ^a   Gastonguay, Marc R ^b  

^a AMGEN INC   (United States)

^b Metrum Research Group   (United States)

Author keywords

Covariate analysis; Darbepoetin alfa; Population PkPd modeling

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLATINUM DERIVATIVE;

ACCURACY; ADULT; AGED; ANALYSIS OF COVARIANCE; ANEMIA; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DIGESTIVE SYSTEM CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; GYNECOLOGIC CANCER; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SYNTHESIS; HUMAN; HYPOTHESIS; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PHARMACODYNAMICS; PHARMACOLOGICAL STIMULATION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STEADY STATE; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

ANEMIA; DRUG THERAPY; ERYTHROPOIETIN; EVALUATION STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS; POPULATION;

EID: 33748748732     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080364     Document Type: Article

References (49)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98.
3. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
4. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebocontrolled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
5. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol. 2003;31:290-299.
6. Agoram B, Sutjandra L, Sullivan J. Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects [abstract]. Clin Pharmacol Ther. 2005;77 (suppl S).
7. Heatherington AC, Schuller J, Mercer AJ. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. Br J Cancer. 2001;84:11-16.
8. Vadhan-Raj S, Mirtsching B, Charu V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapyinduced anemia given darbepoetin alfa every two weeks. J Support Oncol. 2003;1:131-138.
9. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer. 2003;39:2026-2034.
10. Jumbe N, Yao B, Rovetti R, Rossi G, Heatherington AC. Clinical trial simulation of a 200-μg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Huntingt Libr Q. 2002; 16:37-44.
11. Hesketh PJ, Arena F, Patel D, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004;100:859-868.
12. Beguin Y, Loo M, R'Zik S, et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 1993;82:2010-2016.
13. Drueke TB. Modulating factors in the hematopoietic response to erythropoietin. Am J Kidney Dis. 1991;18:87-92.
14. Beguin Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol. 1998;15:S38-S46.
15. Allon M, Kleinman K, Walczyk M, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clin Pharmacol Ther. 2002;72:546-555.
16. Zhang L, Beal SL, Sheiner LB. Simultaneous vs sequential analysis for population PK/PD data I: best-case performance. J Pharmacokinet Pharmacodyn. 2003;30:387-404.
17. Zhang L, Beal SL, Sheinerz LB. Simultaneous vs sequential analysis for population PK/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn. 2003;30:405-416.
18. Gastonguay MR. A full model estimation approach for covariate effects: inference based on clinical importance and estimation precision [abstract]. AAPS J. 2004;6:.
19. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.
20. Burnham KP, Anderson DR. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. New York, NY Springer-Verlag; 2002.
21. Derksen S, Keselman HJ. Backward, forward and stepwise automated subset selection algorithms: frequency of obtaining authentic and noise variables. Br J Math Stat Psychol. 1992;45:265-282.
22. Harrell FE, Jr. Regression Modeling Strategies. New York, NY Springer; 2001.
23. Harrell FE, Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
24. Ribbing J, Jonsson EN. Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model. J Pharmacokinet Pharmacodyn. 2004;31:109-134.
25. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4:E27.
26. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21:457-478.
27. Friberg LE, Brindley CJ, Karlsson MO, Devlin AJ. Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC). Eur J Clin Pharmacol. 2000;56:567-574.
28. Gibaldi M, Perrier D. Pharmacokinetics New York, NY: Marcel Dekker; 1982.
29. Wichmann HE, Loeffler M, Pantel K, Wulff H. A mathematical model of erythropoiesis in mice and rats. Part 2: stimulated erythropoiesis. Cell Tissue Kinet. 1989;22:31-49.
30. Krzyzanski W, Ramakrishnan R, Jusko WJ. Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharmaceut. 1999;27:467-489.
31. Loeffler M, Pantel K, Wulff H, Wichmann HE. A mathematical model of erythropoiesis in mice and rats. Part 1: structure of the model. Cell Tissue Kinet. 1989;22:13-30.
32. Wulff H, Wichmann HE, Pantel K, Loeffler M. A mathematical model of erythropoiesis in mice and rats. Part 3: suppressed erythropoiesis. Cell Tissue Kinet. 1989;22:51-61.
33. Brockmoller J, Kochling J, Weber W, et al. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br J Clin Pharmacol. 1992;34:499-508.
34. Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther. 1992;51:76-89.
35. Chapel SH, Veng-Pedersen P, Schmidt RL, Widness JA. A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther. 2000;295:346-351.
36. Ramakrishnan R, Cheung WY, Farrell F, Joffee L, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther. 2003;306:324-331.
37. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol. 2004;44:991-1002.
38. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-2395.
39. Chapel S, Veng-Pedersen P, Hohl RJ, et al. Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther. 2001;298:820-824.
40. Piroso E, Erslev AJ, Flaharty KK, Caro J. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am J Hematol. 1991;36:105-110.
41. Glaspy J, Henry D, Patel R, et al. The effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005;41:1140-1149.
42. Heatherington AC, Henry D, Patel R, et al. The impact of timing of chemotherapy relative to darbepoetin alfa (DA) on DA pharmacokinetics (PK) and hematologic effects [abstract]. Clin Pharmacol Ther. 2004;75:.
43. Mercadante S, Gebbia V, Marrazzo A, Filosto S. Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev. 2000;26:303-311.
44. Beutler E, Lichtman MA, Coller BS, Kipps TJ. Williams Hematology. New York, NY: McGraw-Hill Inc. 1995.
45. Mahaffy JM, Belair J, Mackey MC. Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis.J Theor Biol. 1998;190:135-146.
46. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci. 2005;26:295-306.
47. Amgen Inc. Aranesp (Darbepoetin aya) Summary of Product Characteristics. Breda, The Netherlands: Amgen Inc; 2005.
48. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
49. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.